Navigation Links
CSL Limited and Talecris Biotherapeutics Agree to Terminate Merger Agreement
Date:6/8/2009

MELBOURNE, Australia and RESEARCH TRIANGLE PARK, N.C., June 8 /PRNewswire/ -- CSL Limited (ASX: CSL) and Talecris Biotherapeutics, Inc. announced today that they have mutually agreed to terminate their merger agreement, announced on August 12, 2008, under which CSL agreed to acquire Talecris for US$3.1 billion in cash.

Dr. Brian McNamee, CEO and Managing Director of CSL Limited, said, "We are disappointed that the U.S. Federal Trade Commission (FTC) resolved to block the transaction. As we have previously stated we fundamentally disagree with the FTC case and matters included in their complaint. Although we continue to believe in the many customer benefits and significant financial synergies that supported the transaction, CSL's Board of Directors did not believe that entering into a protracted litigation process with the FTC, with its inherent risks, substantial costs, and lengthy distraction of CSL management and staff from planning and running our businesses would be in the best interests of our stakeholders."

Dr. McNamee continued, "While we regret that the transaction cannot be completed, CSL remains a well positioned global biopharmaceutical business and will continue to expand on its core strengths. We have consistently produced year-on-year growth for our shareholders and we are confident in the continued value and growth potential of our stand-alone business. We continue to have great respect for Talecris and wish them well in the future."

Lawrence D. Stern, Talecris' Chairman and Chief Executive Officer, said, "After discussions with CSL, we have mutually agreed that litigation regarding the antitrust issue was not the path forward. Based on a careful analysis of the situation and all alternatives available, we believe that termination of the merger agreement is in the best interest of all parties. We are disappointed that patients will not benefit from the efficiencies we saw in the proposed
'/>"/>

SOURCE CSL Limited; Talecris Biotherapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Circ Pharma Limited Enters Into Development Agreement for Chrono Tramadol With Elan Corporation Plc
2. Boston Scientific Acquires Labcoat Limited
3. Red Herring Awards ProGenTech Limited for the 2008 Red Herring Asia 100
4. Bunge Limited Schedules Third Quarter 2008 Earnings Release and Conference Call
5. Solos Endoscopy, Inc. in Final Stages to Upgrade Pink Sheet Status from Limited to Current Information
6. EnrichMap Announces New Program To Reduce Medical Patient Noncompliance And Offers Healthcare Organizations A Limited Trial Test Opportunity
7. Masimo Initiates Limited Release of First-Ever Noninvasive and Continuous Hemoglobin Monitors
8. Non-Safety-Related Voluntary Recall of a Limited Portion of DAYTRANA(TM) (Methylphenidate Transdermal System) Patches Announced
9. Application for Listing of Shire Limited Ordinary Shares
10. Limited transparency in federal nanotech research may hamper development
11. Alimera Sciences, pSivida Limited Amend Medidur(TM) FA Collaboration Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... 27, 2015  Neogen Corporation (NASDAQ: NEOG ) ... United Kingdom -based Lab M Holdings, ... and diagnostic systems. Lab M was ... provider of microbial testing and diagnostic products for the ... company currently sells into more than 70 countries worldwide, ...
(Date:8/27/2015)... 27, 2015 The National Necrotizing Fasciitis ... life—were saved by doctors at Vanderbilt University Hospital in ... NovaBay Pharmaceuticals and Dr. John Crew , director ... Seton Medical Center in Daly City, CA. ... breakthrough approach, pioneered by Dr. Crew, that had previously ...
(Date:8/27/2015)... - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today announced ... 2015. Biorem,s complete second quarter financial statements and MD&A have been ... except earnings per shareThree-months ended , Six -months endedJune 30 , ... , 2014 Revenue , 4,709 , ... , 1,656 , 56 , 3,188 ...
(Date:8/27/2015)... 27, 2015 GlassesOff (OTCBB: GLSO), a ... in the human vision system, announced today a partnership with ... Chris Paul to develop a new mobile app ... improve their real-life on-court performance. Vision is the ... is shooting a ball or blocking a pass. The critical ...
Breaking Biology Technology:Neogen acquires U.K.-based Lab M Holdings 2Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 2Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 3BIOREM Reports $718,000 Net Earnings for the Second Quarter 2BIOREM Reports $718,000 Net Earnings for the Second Quarter 3Eight-Time All-Star Chris Paul and GlassesOff Partner to Develop Innovative Mobile App Designed to Improve On-Court Performance 2Eight-Time All-Star Chris Paul and GlassesOff Partner to Develop Innovative Mobile App Designed to Improve On-Court Performance 3
... 10, 2011 Enobia Pharma Inc., today announced that ... ENB-0040, a bone targeted enzyme replacement therapy being investigated ... bone disorder. The results were presented by Robert Heft, ... the 29th Annual J.P. Morgan Healthcare Conference in San ...
... 10, 2011 Entrega, Inc., a new company ... formation by Enlight Biosciences, a Boston-based company established ... pharmaceutical companies. As part of its initial development ... drug delivery platform to create orally bioavailable formulations ...
... Aratana Therapeutics, a newly-formed company focused on the development of ... it has closed a $20 million Series A financing led ... we will be focused on taking advancements from the human ... and care for animals," said Dr. David Rosen, President and ...
Cached Biology Technology:Enobia Announces Successful Completion of Phase II Juvenile Study of ENB-0040, a Bone Targeted Enzyme Replacement Therapy 2Enobia Announces Successful Completion of Phase II Juvenile Study of ENB-0040, a Bone Targeted Enzyme Replacement Therapy 3New Oral Biologics Delivery Company, Entrega, Announces Strategic Partnership with Pharma 2New Oral Biologics Delivery Company, Entrega, Announces Strategic Partnership with Pharma 3
(Date:8/5/2015)... CHICAGO , August 5, 2015 ... Identity & Access Management Market by Software, Services, Vertical (BFSI, ... Chemical/Pharma), & Geography - Global Forecast to 2020", published ... Access Management Market globally into various segments. The global ... in 2014 to $546.2 Million by 2019, at a ...
(Date:8/3/2015)... Synaptics, Inc. (Nasdaq: SYNA ), the ... members of the executive management team will present to ... Leadership Forum on Tuesday, August 11, 2015 at 1:00 ... the Sonnenalp Resort in Vail, CO. ... information. An audio webcast of the event will be ...
(Date:7/31/2015)... La 10 th International Conference on Genomics ... 22 al 25 de octubre de 2015 en ... conferencia celebra su décimo aniversario. Desde su inauguración en el ... reuniones anuales más influyentes del mundo en el campo ,ómico, ... y mejores a nivel científico. ICG-10 se ...
Breaking Biology News(10 mins):Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3
... CAMBRIDGE, Mass., Oct. 20, 2010 -- Microbes living at the ... of the gaseous waste from the Deepwater Horizon oil spill ... miles of the spill site. A paper on that ... ago today, will appear in a forthcoming issue of the ...
... reducing the cost of certain catalysts substances that ... of super-strong forms of the world,s most widely used ... issue of Chemical & Engineering News (C&EN), ... led to availability of stronger, more durable consumer products ...
... BOSTON (October 20, 2010) - People who consume several ... of refined grains appear to have less of a type ... triggering cardiovascular disease and type 2 diabetes, a new study ... Center on Aging (USDA HNRCA) at Tufts University observed lower ...
Cached Biology News:Microbes may consume far more oil-spill waste than earlier thought 2Eating mostly whole grains, few refined grains linked to lower body fat 2
... expertise that made the original Gene Pulser apparatus ... available has been applied in the Gene Pulser ... modular design of the Gene Pulser II system ... that has the widest range of settings to ...
Caliper offers a wide array of standard LabChip products designed to be used in combination with our AMS 90 and LabChip 3000 microfluidic platforms....
... discovery system miniaturizes, integrates and automates ... LabChip technology, the LabChip 3000 performs ... flow fashion. LabChip assays are separations-based, ... what is achievable in homogenous, well-based ...
...
Biology Products: